. Author manuscript; available in PMC: 2011 Jun 15.

Published in final edited form as: Clin Cancer Res. 2010 Apr 16;16(12):3232–3239. doi: 10.1158/1078-0432.CCR-10-0122

Table 4. Incremental enhancement in AUC for prediction of any cancer attributable to each of the additional kallikreins.

Results are presented separately for the Rotterdam cohort and Göteborg cohort (7), when models are developed among unscreened men and independently validated among recently screened men

	Rotterdam Cohort		Göteborg Cohort

	AUC (95% CI)	Incremental enhancement	AUC (95% CI)	Incremental enhancement
Laboratory models
Full: age, tPSA, fPSA, iPSA, hK2	0.713 (0.682, 0.743)	--	0.656 (0.621, 0.691)	--
Without fPSA	0.576 (0.542, 0.610)	0.137	0.620 (0.583, 0.657)	0.036
Without iPSA	0.669 (0.637, 0.701)	0.044	0.660 (0.625, 0.695)	-0.004
Without hK2	0.701 (0.671, 0.732)	0.012	0.592 (0.556, 0.629)	0.064
Clinical models
Full: DRE, age, tPSA, fPSA, iPSA, hK2	0.711 (0.681, 0.741)	--	0.678 (0.643, 0.712)	--
Without fPSA	0.606 (0.573, 0.640)	0.105	0.651 (0.614, 0.687)	0.027
Without iPSA	0.679 (0.648, 0.710)	0.032	0.683 (0.648, 0.718)	-0.005
Without hK2	0.700 (0.670, 0.731)	0.011	0.632 (0.596, 0.669)	0.046